Dr. Jack West reviews the encouraging results with selumetinib, a MEK inhibitor, in combination with chemotherapy for patients with advanced NSCLC and a KRAS mutation, the most common molecular marker seen in lung cancer.
Dr. Jack West offers thoughts on the disappointing negative results of the START trial with the immunotherapy Stimuvax, and what this might mean as we anticipate the results of future trials of other immunotherapies moving forward in clinical trials in lung cancer.
Dr. Jack West discusses the likely biological underpinnings of a mixed response to treatment for advanced lung cancer and the potential utility of multiple biopsies to learn more about biological changes over time and in different tumor areas.
Dr. Jack West describes what a mixed response is and how it can be interpreted and managed for advanced lung cancer.
Dr. Jack West describes his evolving perspective on the yield of testing for molecular markers, which is leading him to become more optimistic about testing a broader range of people with NSCLC.
Dr. Jack West reviews what situations would make a "local" treatment like radiation appropriate in a situation where a patient has known advanced/metastatic lung cancer.
Dr. H. Jack West reviews the TOPICAL study of Tarceva vs. placebo for marginal and poor PS patients with advanced NSCLC, which showed a clearly superior outcome with Tarceva in patients who developed a rash vs. those who don't.
Dr. H. Jack West, medical oncologist from Swedish Cancer Institute in Seattle, WA, reviews the rationale for giving chemotherapy to patients with NSCLC even when it appears that the cancer is limited to the chest.
Dr. H. Jack West, medical oncologist from Swedish Cancer Institute in Seattle, WA, reviews the general principles of treating locally advanced non-small cell lung cancer (NSCLC).
Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by EGFR inhibitors or chest radiation.
Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.
Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.
Dr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.
Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer.
Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).
Dr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).
Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.
Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.
Drs. Ramaswamy Govindan from Washington University and Julie Brahmer from Johns Hopkins University answer questions about the current evidence and emerging research on immune-based treatments for lung cancer.
Dr. Julie Brahmer reviews science and early trial results for immunotherapies for lung cancer ranging from cancer vaccines to anti-cancer viruses.
Dr. Ramaswamy Govindan provides a summary of the science behind several promising immunotherapies for lung cancer and the clinical trials that could lead to them being integrated into our treatment plans.
Dr. Glen Goss, University of Ottawa and NCI-Canada Lung Cancer Committee chair, discusses the potential and limitations of integrating molecular marker studies in advanced non-small cell lung cancer patients across a health care system.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the benefits and challenges of conducting trials that include patient subgroups based on molecular markers.
Panel discussion with 4 expert thought leaders in lung cancer about how we might best approach testing clinically relevant molecular targets in lung cancer patients.
Panel discussion with 4 expert thought leaders in lung cancer about the prevalence of critical molecular markers in different clinical and histologic groups of lung cancer patients.
Dr. Alice Shaw from Massachusetts General Hospital reviews the frequency of molecular markers in lung cancer by patient sex, smoking status, race, and histology.
Dr. Charles Rudin from Johns Hopkins covers the work from the Lung Cancer Mutation Consortium that identified a wide range of molecular markers in patients with lung adenocarcinoma.
